- 62. (Amended) The method of claim 57, wherein said polypeptide is formulated in a pharmaceutical composition comprising a pharmaceutically acceptable carrier.
- 89. (Amended) The method of claim 88, wherein said polypeptide is formulated in a pharmaceutical composition comprising a pharmaceutically acceptable carrier.
- 92. (Amended) The method of claim 82, wherein said polypeptide further comprises Met at the N-terminus.
- 93. (Amended) The method of claim 82, wherein said polypeptide is unglycosylated.
- 95. (Amended) The method of claim 82, wherein the polypeptide consists of (a) a sufficient number of amino acids 32-64 of Figure 7 that said polypeptide has epithelial cell specificity, and (b) amino acids 65-194 of Figure 7.
- 150. (Amended) A method of stimulating epithelial cells comprising administering to a patient in need thereof an epithelial cell stimulating amount of a keratinocyte growth factor (KGF) polypeptide prepared by expressing a DNA encoding a polypeptide comprising amino acids 32 194 of Figure 7.
- 154. (Amended) The method of claim 150, wherein said DNA is expressed in a bacterial cell, a fungal cell, a mammalian cell or an insect cell.
- 155. (Amended) A method of stimulating epithelial cells comprising administering to a patient in need thereof an epithelial cell stimulating amount of a keratinocyte growth factor (KGF) polypeptide comprising amino acids 32 to 194 of Figure 7 or a segment of said polypeptide, wherein said polypeptide and said segment of said polypeptide have mitogenic activity on BALB/MK cells.
- 163. (Amended) A method of stimulating epithelial cells comprising administering to a patient in need thereof an epithelial cell stimulating amount of a keratinocyte growth factor (KGF) polypeptide comprising amino acids 32-194 of Figure 7 or a segment of said polypeptide, wherein the segment is that part of the amino acid sequence of Figure 7 that

remains after the amino acid sequence of Figure 7 is truncated from an N terminus to C terminus direction, within the region of amino acids 32-78.

- 165. (Amended) The method of claim 163 wherein said polypeptide and said segment of said polypeptide has mitogenic activity on BALB/MK keratinocyte cells.
- 166. (Amended) The method of claim 163, wherein said polypeptide and said segment of said polypeptide stimulates mitogenic activity on epithelial cells.
- 167. (Amended) A method of stimulating epithelial cells comprising administering to a patient in need thereof an epithelial cell stimulating amount of a keratinocyte growth factor (KGF) polypeptide comprising a keratinocyte growth factor (KGF) polypeptide comprising amino acids 32-194 of Figure 7 or a segment of said polypeptide, wherein the segment is that part of the amino acid sequence of Figure 7 that remains after the amino acid sequence of Figure 7 is truncated from the C terminus toward the N terminus, within the region of amino acids 194 to 189.
- 169. (Amended) The method of claim 167, wherein said polypeptide and said segment of said polypeptide have mitogenic activity on BALB/MK keratinocyte cells.
- 170. (Amended) The method of claim 167, wherein said polypeptide and said segment of said polypeptide stimulates mitogenic activity in epithelial cells.
- 171. (Amended) A method of stimulating epithelial cells comprising administering to a patient in need thereof an epithelial cell stimulating amount of a keratinocyte growth factor (KGF) polypeptide comprising amino acids 32-194 of Figure 7 or a segment of said polypeptide, wherein the segment is that part of the amino acid sequence of Figure 7 that remains after the amino acid sequence of Figure 7 is truncated from an N terminus to C terminus direction, within the region of amino acids 32-78 and is truncated from the C terminus toward the N terminus, within the region of amino acids 194 to 189.
- 173. (Amended) The method of claim 171, wherein said polypeptide and said segment of said polypeptide have mitogenic activity on BALB/MK keratinocyte cells.
- 174. (Amended) The method of claim 171, wherein said polypeptide and said segment of said polypeptide stimulates mitogenic activity in epithelial cells.

- 177. (Amended) A method of stimulating epithelial cells comprising administering to a patient in need thereof an epithelial cell stimulating amount of a keratinocyte growth factor (KGF) polypeptide, wherein said polypeptide is prepared by expressing a DNA encoding a polypeptide comprising amino acids 32-194 of Figure 7 or a segment of said polypeptide, wherein the segment is that part of the amino acid sequence of Figure 7 that remains after the amino acid sequence of Figure 7 is truncated from an N terminus to C terminus direction, within the region of amino acids 32-78.
- 178. (Amended) The method of claim 177, wherein the DNA is expressed in a bacterial cell, a fungal cell, a mammalian cell or an insect cell.
- 180. (Amended) The method of claim 177, wherein said polypeptide and said segment of said polypeptide has mitogenic activity on BALB/MK keratinocyte cells.
- 181. (Amended) A method of stimulating epithelial cells comprising administering to a patient in need thereof an epithelial cell stimulating amount of a keratinocyte growth factor (KGF) polypeptide comprising amino acids 32 to 194 of Figure 7 or a segment of said polypeptide, wherein said polypeptide and said segment of said polypeptide stimulates mitogenic activity in epithelial cells.
- 190. (Amended) A method of stimulating epithelial cells comprising administering to a patient in need thereof an epithelial cell stimulating amount of a keratinocyte growth factor (KGF) polypeptide comprising a segment of amino acids 32-194 of Figure 7, wherein the segment is that part of the amino acid sequence of Figure 7 that remains after the amino acid sequence of Figure 7 is truncated from an N terminus to C terminus direction, within the region of amino acids 32-78, and wherein said polypeptide is unglycosylated.
- 191. (Amended) The method of one of claims 150-151, 153-174, 177-189, wherein said polypeptide is unglycosylated.
- 192. (Amended) The method of one of claims 150-151, 153-174, 177-189, wherein said polypeptide is glycosylated.